Biosidus

Biosidus

Argentina‑based biosimilar leader delivering affordable biologics to emerging markets.

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Estimated funding: $50M

AI Company Overview

Argentina‑based biosimilar leader delivering affordable biologics to emerging markets.

OncologyRheumatologyEndocrinologyImmunology

Technology Platform

A recombinant protein platform using CHO and yeast expression systems, coupled with proprietary purification and formulation processes to produce high‑quality biosimilars.

Opportunities

Expanding biosimilar access in emerging markets and leveraging partnerships for regional distribution.

Risk Factors

Regulatory hurdles, competition from multinational biosimilar manufacturers, and scaling manufacturing capacity.

Competitive Landscape

Competes with global biosimilar players like Sandoz, Amgen, and Pfizer, differentiating through localized patient support and cost‑effective production.